New data shows Sandoz’s Enbrel biosimilar has equivalent efficacy profile
pharmafile | July 7, 2016 | News story | Research and Development, Sales and Marketing | Amgen, EMA, Enbrel, FDA, Novartis, Sandoz, biosimilars
Sandoz has announced new data confirming the equivalent safety and efficacy profile of their biosimilar version of Enbrel (etanercept) in patients with moderate-to-severe chronic plaque-type psoriasis.
The Novartis division recently presented data at the European Congress of Rheumatology (EULAR 2016) demonstrating the pharmacokinetic bioequivalence of this, and other, biosimilars. The company has already submitted their biosimilar version of Enbrel to the EMA and FDA for approval.
In the EGALITY trial, presented at the 5th Congress of the Psoriasis International Network in Paris, the biosimilar met the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
Malte Peters, head of global clinical development in biopharmaceuticals at Sandoz, says: “The EGALITY data, showing our biosimilar etanercept to be bioequivalent to the originator product, is part of the comprehensive data package submitted to the EMA and the FDA. If our biosimilar etanercept is approved for the same indications as the originator product, more patients with chronic inflammatory conditions like rheumatoid arthritis and psoriasis will have access to life-changing biologic treatment options.”
The makers of the originator product, Amgen, have been pursuing methods to protect the sales of their blockbuster drug and prevent Sandoz’s biosimilar getting to market. This included filing a suit in a US court to prevent sales of the biosimilar if the FDA were to approve it.
Sandoz is seeking approval in all of Enbrel’s current indications in its regulatory submission. Decisions from the regulators are expected later this year.
Sean Murray
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …
